T-ALL engraftment in NSG mice
Bulk T-ALL cell dose . | Patient samples . | No. of engrafted/total no. of injected . |
---|---|---|
1 × 107 | 5747, 4289 | 5/5 |
7 × 106 | 7017, 80150 | 7/8 |
1 × 106 | 80150, 5747, 4289, 90205 | 12/14 |
8.3 × 105 | 5747 | 2/2 |
7 × 105 | 7017, 80150 | 7/9 |
1 × 105 | 80150, 5747, 90205 | 11/14 |
7 × 104 | 7017, 80150 | 4/10 |
1 × 104 | 80150, 5747, 90205 | 8/13 |
7 × 103 | 7017, 80150 | 2/10 |
1 × 103 | 80150, 90205 | 2/5 |
Bulk T-ALL cell dose . | Patient samples . | No. of engrafted/total no. of injected . |
---|---|---|
1 × 107 | 5747, 4289 | 5/5 |
7 × 106 | 7017, 80150 | 7/8 |
1 × 106 | 80150, 5747, 4289, 90205 | 12/14 |
8.3 × 105 | 5747 | 2/2 |
7 × 105 | 7017, 80150 | 7/9 |
1 × 105 | 80150, 5747, 90205 | 11/14 |
7 × 104 | 7017, 80150 | 4/10 |
1 × 104 | 80150, 5747, 90205 | 8/13 |
7 × 103 | 7017, 80150 | 2/10 |
1 × 103 | 80150, 90205 | 2/5 |
Engraftment was considered as positive if there was > 2% human CD45+CD7+CD5+ cells in the RF as detected by flow cytometry. Limiting dilution analysis using L-Calc software found that L-IC frequency is 1 in 6.3 × 105 cells (95% confidence interval from 1 in 4.0 × 105 to 1 in 1.0 × 107).